Bars

Brand : Xolair | Product Group : Health | Pharmaceutical Products | Name of Agency : Watermelon | City of Agency : Mumbai | Country Of Agency : India | Client : Novartis | Work type : Client work | Date of publication / release : Oct 10, 2008 | Body copy :

Capture IgE

90% of allergic asthma is mediated by IgE, a cause of asthma inflammation. Anti-igE therapy is an innovative therapy that selectively targets a root cause of inflammation in allergic asthma. Anti-IgE therapy inhibits the inflammatory cascade before it starts and may become a new add-on treatment solution for moderate and severe patients who remain symptomatic despite standard treatment.

Change the way asthamatics live with severe allergic asthama.

| Views : 2